Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL): CHRONOS-3 and CHRONOS-4 Meeting Abstract
| Authors: | Gerecitano, J.; Zheng, H.; Mongay Soler, L.; Ito, R.; Reis, D.; Lu, C.; Shen, J.; Childs, B. H.; Zinzani, P. L. |
| Abstract Title: | Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL): CHRONOS-3 and CHRONOS-4 |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx373.040 |
| Language: | English |
| ACCESSION: | WOS:000411324002222 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx373.040 |
| Notes: | Meeting Abstract: 1034TiP -- Appears on page 368 of the abstract book -- Source: Wos |
